AbbVie Inc. has entered into an underwriting agreement to issue and sell nine series of senior notes with an aggregate principal amount of $10.0 billion. The company expects to receive net proceeds of approximately $9.93 billion from the offering.
Key Details
- Offering Size: The offering consists of $10.0 billion in senior notes, including both fixed and floating rate tranches, with maturities ranging from 2028 to 2066.
- Use of Proceeds: The primary use of the net proceeds will be to fund a portion of the cash payment for the acquisition of Apogee Therapeutics, Inc. and related expenses. The funds will also be used for general corporate purposes, including potential debt repayment.
- Closing Date: The sale of the notes is expected to close on August 18, 2026, subject to customary closing conditions.